Durect (Durect) Interest Expense : $-2.79 Mil (TTM As of Dec. 2023)

View and export this data going back to 2000. Start your Free Trial

What is Durect Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Durect's interest expense for the three months ended in Dec. 2023 was $ -0.62 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2023 was $-2.79 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Durect's Operating Income for the three months ended in Dec. 2023 was $ -6.25 Mil. Durect's Interest Expense for the three months ended in Dec. 2023 was $ -0.62 Mil. Durect did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Durect Interest Expense Historical Data

The historical data trend for Durect's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Durect Interest Expense Chart

Durect Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

Get a 7-Day Free Trial

-2.50

-2.24

-2.15

-2.40

-2.79

Durect Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Interest Expense	Get a 7-Day Free Trial															-0.65	-0.73	-0.75	-0.70	-0.62

Durect Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.79 Mil.

Durect (NAS:DRRX) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Durect's Interest Expense for the three months ended in Dec. 2023 was $-0.62 Mil. Its Operating Income for the three months ended in Dec. 2023 was $-6.25 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Dec. 2023 was $2.70 Mil.

Durect's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as

Durect did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

Durect (Durect) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Durect Corp (NAS:DRRX) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

DC8A:Germany

Address

10260 Bubb Road, Cupertino, CA, USA, 95014

Website

https://www.durect.com

Durect Corp is a biopharmaceutical company. It is engaged in the research, development, and manufacturing of pharmaceutical products. The company develops pharmaceutical products based on two categories which include new chemical entities and proprietary pharmaceutical programs. The company's pipeline products consist of DUR-928, POSIMIR, and others. Geographically, the company operates in the United States, Europe, Japan, and other countries, of which key revenue is derived from the Europe .

Executives

Judith J. Robertson	director	10260 BUBB ROAD, CUPERTINO CA 95014
Gail J Maderis	director	364 LOMBARD ST., SAN FRANCISCO CA 94133
Timothy M. Papp	officer: Chief Financial Officer	C/O DURECT CORPORATION, 10260 BUBB ROAD, CUPERTINO CA 95014
Gail M Farfel	director	142 TEMPLE STREET, SUITE 205, NEW HAVEN CT 06510
Mohammad Azab	director	C/O SUPERGEN, INC., 4140 DUBLIN BLVD., SUITE 200, DUBLIN CA 94568
Peter S Garcia	director	ALX ONCOLOGY HOLDINGS INC., 866 MALCOLM ROAD, SUITE 100, BURLINGAME CA 94010
Simon X Benito	director	967 LAWRENCE AVE, WESTFIELD NJ 07090
Norman Sussman	officer: Chief Medical Officer	C/O DURECT CORP., 10260 BUBB ROAD, CUPERTINO CA 95014
Bleichroeder Lp	10 percent owner	1345 AVENUE OF THE AMERICAS, 47TH FLOOR, NEW YORK NY 10105
Judy R Joice	officer: Sr. VP Operations & Corp QA	10260 BUBB ROAD, CUPERTINO CA 95014
21 April Fund Lp	10 percent owner	1345 AVENUE OF THE AMERICAS, 47TH FLOOR, New York NY 10105
Jon S Saxe	director	FIRST HORIZON PHARMACEUTICAL CORP, 660 HEMBREE PKWY STE 106, ROSWELL GA 30076
Michael Arenberg	officer: Chief Financial Officer	10260 BUBB ROAD, CUPERTINO CA 95014
James E Brown	director, officer: President & CEO	10240 BUBB RD, CUPERTINO CA 95014
First Eagle Investment Management, Llc	10 percent owner	1345 AVENUE OF THE AMERICAS, NEW YORK NY 10105